Opus Genetics
IRD
38 hedge funds and large institutions have $4.62M invested in Opus Genetics in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 10 closing their positions.
76,400% more call options, than puts
Call options by funds: $765K | Put options by funds: $1K
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
1.54% more ownership
Funds ownership: 10.9% → 12.44% (+1.5%)
7% less funds holding
Funds holding: 41 → 38 (-3)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
31% less capital invested
Capital invested by funds: $6.69M → $4.62M (-$2.07M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$451K |
| 2 |
RB
Richmond Brothers
Jackson,
Michigan
|
+$424K |
| 3 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$415K |
| 4 |
BlackRock
New York
|
+$83.9K |
| 5 |
Millennium Management
New York
|
+$80.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$401K |
| 2 |
Two Sigma Advisers
New York
|
-$214K |
| 3 |
Two Sigma Investments
New York
|
-$168K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$68K |
| 5 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$60K |
IRD Hedge Fund Activity: Q2 2022 in Review
38 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q2 2022, worth a combined $4.62M — down 31% from $6.69M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of IRD and 8 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 11 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $451K. The largest seller was Ikarian Capital, exiting entirely with an estimated $401K sold.
- 38 institutional investors held Opus Genetics (IRD) as of Q2 2022, down from 41 in Q1 2022.
- Funds reported $4.62M of Opus Genetics stock for Q2 2022, down 31% quarter-over-quarter.
- 8 funds opened new Opus Genetics positions in Q2 2022 and 10 closed out, a net change of -2 holders.
- The largest Opus Genetics buyer in Q2 2022 was Renaissance Technologies, an estimated $451K added.
- The largest Opus Genetics seller in Q2 2022 was Ikarian Capital, an estimated $401K sold.
Based on aggregated 13F filings for Q2 2022.